MannKind Corporation (NASDAQ:MNKD) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the MannKind Corporation Third Quarter 2025 Financial Results Earnings Call.
Mannkind Corp (MNKD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 11,414,671 | $61,296,783 | 0.69% | |
| 2. | Nitorum Capital Seth Rosen | 6,561,465 | $35,235,067 | -7% | 6.19% |
| 3. | VenBio Select Advisor Kurt Von Emster | 4,468,877 | $23,997,869 | -24% | 0.31% |
| 4. | Eversept Partners Kamran Moghtaderi | 2,042,727 | $10,969,444 | +193% | 0.76% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,831,327 | $9,834,226 | -46% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.93 | 791 | $2,317.63 | 728,997 | 2022-07-31 | Filing | |
| $2.93 | 3,147 | $9,220.71 | 2,084,486 | 2022-07-31 | Filing | |
| $2.93 | 4,581 | $13,422.33 | 830,650 | 2022-07-31 | Filing | |
| $2.93 | 5,000 | $14,650.00 | 781,690 | 2022-07-31 | Filing | |
| $2.71 | 36,900 | $99,999.00 | 576,690 | 2022-02-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.03 | 18,777 | $94,448.31 | 455,211 | 2025-11-14 | Filing | |
| $5.34 | 47,000 | $250,980.00 | 1,032,013 | 2025-09-16 | Filing | |
| $3.94 | 75,367 | $296,945.98 | 830,508 | 2025-07-16 | Filing | |
| $3.94 | 7,466 | $29,416.04 | 841,719 | 2025-07-16 | Filing | |
| $4.00 | 64,085 | $256,340.00 | 925,258 | 2025-06-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 28,710,136 | $154,173,430 | 0% | |
| 2. | 17,630,583 | $94,676,230 | 0% | |
| 3. | 10,740,198 | $57,674,863 | 0% | |
| 4. | 7,385,513 | $39,666,541 | 0% | |
| 5. | 5,194,739 | $27,895,748 | 0% |
News See All
H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)
MannKind Corporation (NASDAQ:MNKD) is one of the best long-term penny stocks to buy right now. On August 25, H.C.
14 Best Long-Term Penny Stocks to Buy Right Now
On August 29, Ed Yardeni, President of Yardeni Research, appeared on CNBC’s ‘Closing Bell’ to talk about the latest news impacting markets, the possible factors that might inspire the next market...
MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company developing inhaled therapeutic products for endocrine and orphan lung diseases.
Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7
MannKind Corporation (NASDAQ:MNKD) is one of the top strong buy stocks under $5 to buy now.
15 Strong Buy Stocks Under $5 to Buy Now
On August 22, Tom Lee, head of research and chief investment officer of Fundstrat Capital, appeared on CNBC’s ‘Squawk on the Street’ to talk about what he thinks about Fed Chair Powell’s speech...
10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
Leerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT
MannKind Corporation (NASDAQ:MNKD) is one of the Most Oversold Penny Stocks to Buy Now.
11 Most Oversold Penny Stocks to Buy Now
On August 20, Venu Krishna, the head of US equity strategy at Barclays, joined CNBC television to discuss the probable market response to the Federal Reserve's policy signals, particularly in light of...
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
MannKind Corporation (NASDAQ:MNKD)’s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients.
Hedge Fund Resource Center Billionaire Hedge Funds
